The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial
Open accessAbstract
There is an urgent need for first-line treatment options for patients with human epidermal growth factor receptor 2 (HER2)-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma. Claudin-18 isoform 2 (CLDN18.2) is expressed in normal gastric cells and maintained in malignant G/GEJ adenocarcinoma cells. GLOW (closed enrollment), a global, double-blind, phase 3 study, examined zolbetuximab, a monoclonal antibody that targets CLDN18.2, plus capecitabine and oxaliplatin (CAPOX) as first-line treatment for CLDN18.2-positive, HER2-negative, locally advanced unresectable or mG/GEJ adenocarcinoma. Patients ( n = 507) were randomized 1:1 (block sizes of two) to zolbetuximab plus CAPOX or placebo plus CAPOX. GLOW met the primary endpoint of progression-free survival (median, 8.21 months versus 6.80 months with zolbetuximab versus placebo; hazard ratio (HR) = 0.687; 95% confidence interval (CI), 0.544–0.866; P = 0.0007) and key secondary endpoint of overall survival (median, 14.39 months versus 12.16 months; HR = 0.771; 95% CI, 0.615–0.965; P = 0.0118). Grade ≥3 treatment-emergent adverse events were similar with zolbetuximab (72.8%) and placebo (69.9%). Zolbetuximab plus CAPOX represents a potential new first-line therapy for patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or mG/GEJ adenocarcinoma. ClinicalTrials.gov identifier: NCT03653507 .
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Several CLDN18.2-targeting therapies have demonstrated efficacy in clinical trials for GI cancers, including antibodies, antibody-drug conjugates (ADC), and CAR-T cells (64–66).”
From Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer (2024) · cites this paper as [65]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302
Self-citationSmyth, E. C., Nilsson, M., Grabsch, H. I., van Grieken, N. C., & Lordick, F. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31288-5 · Cited by 4,803
Self-citationJanjigian, Y. Y., Shitara, K., Moehler, M., Garrido, M., Salman, P., Shen, L., Wyrwicz, L., Yamaguchi, K., Skoczylas, T., Campos Bragagnoli, A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00797-2 · Cited by 3,041
Self-citationWilke, H., Muro, K., Van Cutsem, E., Oh, S.-C., Bodoky, G., Shimada, Y., Hironaka, S., Sugimoto, N., Lipatov, O., Kim, T.-Y., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70420-6 · Cited by 2,438
Self-citationFuchs, C. S., Tomasek, J., Yong, C. J., Dumitru, F., Passalacqua, R., Goswami, C., Safran, H., dos Santos, L. V., Aprile, G., Ferry, D. R., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61719-5 · Cited by 2,188
Van Cutsem, E., Sagaert, X., Topal, B., Haustermans, K., & Prenen, H. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30354-3 · Cited by 1,793
Japanese gastric cancer treatment guidelines 2018 (5th edition)
Japanese Gastric Cancer Association (2021) · Gastric Cancer · doi:10.1007/s10120-020-01042-y · Cited by 1,749
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Lordick, F., Carneiro, F., Cascinu, S., Fleitas, T., Haustermans, K., Piessen, G., Vogel, A., & Smyth, E. C. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.07.004 · Cited by 1,503
Self-citationJapanese Gastric Cancer Association
(2007) · Encyclopedia of Cancer and Society · doi:10.4135/9781412953979.n332 · Cited by 1,261
Cited by
Exploring treatment options in cancer: tumor treatment strategies
Liu, B., Zhou, H., Tan, L., Siu, K. T. H., & Guan, X.-Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01856-7 · Cited by 1,201
Sundar, R., Nakayama, I., Markar, S. R., Shitara, K., van Laarhoven, H. W. M., Janjigian, Y. Y., & Smyth, E. C. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00052-2 · Cited by 393
Self-citationYang, H., Wang, F., Hallemeier, C. L., Lerut, T., & Fu, J. (2024) · The Lancet · doi:10.1016/s0140-6736(24)02226-8 · Cited by 299
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Dilly, J., Hoffman, M. T., Abbassi, L., Li, Z., Paradiso, F., Parent, B. D., Hennessey, C. J., Jordan, A. C., Morgado, M., Dasgupta, S., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0177 · Cited by 308
Cancer therapy with antibodies
Paul, S., Konig, M. F., Pardoll, D. M., Bettegowda, C., Papadopoulos, N., Wright, K. M., Gabelli, S. B., Ho, M., van Elsas, A., & Zhou, S. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00690-x · Cited by 248
Metadata
- Authors
- Shah, M. A., Shitara, K., Ajani, J. A., Bang, Y.-J., Enzinger, P., Ilson, D., Lordick, F., Van Cutsem, E., Gallego Plazas, J., Huang, J., Shen, L., Oh, S. C., Sunpaweravong, P., Soo Hoo, H. F., Turk, H. M., Oh, M., Park, J. W., Moran, D., Bhattacharya, P., Arozullah, A., & Xu, R.-H.
- Affiliations
- Weill Cornell Medicine (US)
- National Cancer Center Hospital East (JP)
- The University of Texas MD Anderson Cancer Center (US)
- Seoul National University (KR)
- Dana-Farber Cancer Institute (US)
- Memorial Sloan Kettering Cancer Center (US)
- University Hospital Leipzig (DE)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking University Cancer Hospital (CN)
- Korea University Guro Hospital (KR)
- Prince of Songkla University (TH)
- Astellas Pharma (United States) (US)
- Sun Yat-sen University (CN)
- Corresponding author
- Xu, Rui-Hua
- ORCID
- Venue
- Nature Medicine
- Published
- 2023-07-31
- Volume
- 29
- Issue
- 8
- Pages
- 2133-2141
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC10427418
- OpenAlex
- W4385429828
- Cited by
- 681
- References
- 35
- Citations by year
- 2026: 274 · 2025: 221 · 2024: 162 · 2023: 24
- FWCI
- 125.47
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Lirias (submittedVersion, cc-by)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Greater South Information System
- Funders
- Astellas Pharma Inc.
- Topics
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Health Sciences › Medicine › Surgery › Esophageal Cancer Research and Treatment
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Keywords
- zolbetuximab, CLDN18.2, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, HER2-negative, capecitabine, oxaliplatin, XELOX, first-line therapy, progression-free survival, overall survival, monoclonal antibodies
- MeSH terms
- Capecitabine, Oxaliplatin, Adenocarcinoma, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Esophageal Neoplasms, Esophagogastric Junction, Humans, Stomach Neoplasms, Claudins, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. https://app.cochat.ai/papers/10.1038/s41591-023-02465-7
- The paper
- Shah, M. A., Shitara, K., Ajani, J. A., Bang, Y.-J., Enzinger, P., Ilson, D., Lordick, F., Van Cutsem, E., Gallego Plazas, J., Huang, J., Shen, L., Oh, S. C., Sunpaweravong, P., Soo Hoo, H. F., Turk, H. M., Oh, M., Park, J. W., Moran, D., Bhattacharya, P., . . . Xu, R.-H. (2023). Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nature Medicine. https://doi.org/10.1038/s41591-023-02465-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.